These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31397188)

  • 1. Changes in serum adipokines profile and insulin resistance in patients with rheumatoid arthritis treated with anti-TNF-
    Corrado A; Colia R; Rotondo C; Sanpaolo E; Cantatore FP
    Curr Med Res Opin; 2019 Dec; 35(12):2197-2205. PubMed ID: 31397188
    [No Abstract]   [Full Text] [Related]  

  • 2. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis.
    Seriolo B; Paolino S; Sulli A; Fasciolo D; Cutolo M
    Ann N Y Acad Sci; 2006 Jun; 1069():414-9. PubMed ID: 16855168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study.
    Onsun N; Akaslan TÇ; Sallahoglu K; Gülcan AS; Bulut H; Yabacı A
    J Dermatolog Treat; 2022 May; 33(3):1727-1732. PubMed ID: 33704001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis.
    Tam LS; Tomlinson B; Chu TT; Li TK; Li EK
    Clin Rheumatol; 2007 Sep; 26(9):1495-8. PubMed ID: 17237906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
    García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
    Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug outcome survey to evaluate anti-TNF treatment in rheumatoid arthritis: an Italian observational study (the DOSE study).
    Anecchino C; Fanizza C; Marino V; Romero M;
    Clin Exp Rheumatol; 2015; 33(6):779-87. PubMed ID: 26575614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic blockade of TNF-α does not improve insulin resistance in humans.
    Ferraz-Amaro I; Arce-Franco M; Muñiz J; López-Fernández J; Hernández-Hernández V; Franco A; Quevedo J; Martínez-Martín J; Díaz-González F
    Horm Metab Res; 2011 Oct; 43(11):801-8. PubMed ID: 22009376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
    Gonzalez-Gay MA; Vazquez-Rodriguez TR; Garcia-Unzueta MT; Berja A; Miranda-Filloy JA; de Matias JM; Gonzalez-Juanatey C; Llorca J
    Clin Exp Rheumatol; 2010; 28(1):56-62. PubMed ID: 20346239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
    Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
    Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis.
    Gonzalez-Gay MA; Garcia-Unzueta MT; Berja A; Gonzalez-Juanatey C; Miranda-Filloy JA; Vazquez-Rodriguez TR; de Matias JM; Martin J; Dessein PH; Llorca J
    Clin Exp Rheumatol; 2009; 27(2):222-8. PubMed ID: 19473561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis.
    Gonzalez-Gay MA; De Matias JM; Gonzalez-Juanatey C; Garcia-Porrua C; Sanchez-Andrade A; Martin J; Llorca J
    Clin Exp Rheumatol; 2006; 24(1):83-6. PubMed ID: 16539824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement.
    Bouman C; van Herwaarden N; van den Hoogen F; van der Maas A; van den Bemt B; den Broeder AA
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):597-604. PubMed ID: 28425772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [TNF inhibitors].
    Kameda H
    Nihon Rinsho; 2016 Jun; 74(6):957-62. PubMed ID: 27311185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology.
    Czókolyová M; Pusztai A; Végh E; Horváth Á; Szentpéteri A; Hamar A; Szamosi S; Hodosi K; Domján A; Szántó S; Kerekes G; Seres I; Harangi M; Paragh G; Szekanecz É; Szekanecz Z; Szűcs G
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.
    Halvorsen EH; Haavardsholm EA; Pollmann S; Boonen A; van der Heijde D; Kvien TK; Molberg Ø
    Ann Rheum Dis; 2009 Feb; 68(2):249-52. PubMed ID: 18723564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy.
    Pina T; Genre F; Lopez-Mejias R; Armesto S; Ubilla B; Mijares V; Dierssen-Sotos T; Gonzalez-Lopez MA; Gonzalez-Vela MC; Blanco R; Hernández JL; Llorca J; Gonzalez-Gay MA
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1995-2001. PubMed ID: 25823684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis.
    Hoffman E; Rahat MA; Feld J; Elias M; Rosner I; Kaly L; Lavie I; Gazitt T; Zisman D
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.